Project description
Next-generation platform for the production of high-value active compounds
With the support of the EU-funded AlkaBurst2.0 project, France-based company Alkion BioInnovations will introduce a breakthrough biorefinery to produce top-quality active pharmaceutical ingredients in a sustainable and cost-effective way. The core technology of the biotech company will combine patented automated bioreactor technology – AlkaBurst2.0 – with unique know-how on gene expression methods, culture media and extraction. The process will enable standardised production of safe and clean active pharmaceutical ingredients, saving significant amount of time, space, electricity and water consumption
Objective
Alkion, a revolutionary biotech company, is developing a breakthrough biorefinery to produce top quality active pharmaceutical ingredients (API) and extracts in plants in a sustainable and cost-effective way. Our core technology combines our disruptive patented automated bioreactor-AlkaBurst2.0 with unique knowhow on gene expression methods, culture media and extraction. Our process offers high productivity and a low carbon footprint.
The pharma industry is carbon intensive with recurring problems of quality & safety. Moreover, many critical APIs are outsourced to Asia to cut costs. AlkaBurst2.0 allows a local standardised production of safe & clean APIs in its automated process saving 75% time, 80% space, 95% electricity, 98% water.
We first validated the production for Covid-19 natural vaccine adjuvants QS21/7, cannabinoids & certain recombinant proteins for the urgent market demand. We need €7.5M to build & validate our pilot and expect to generate €125M revenue by 2028 with 105 job
Fields of science
- engineering and technologyenvironmental biotechnologybioremediationbioreactors
- engineering and technologyenvironmental engineeringenergy and fuelsrenewable energy
- medical and health scienceshealth sciencesinfectious diseasesRNA virusescoronaviruses
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- social scienceseconomics and businesseconomicssustainable economy
Programme(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Funding Scheme
HORIZON-AG - HORIZON Action Grant Budget-BasedCoordinator
92100 BOULOGNE BILLANCOURT
France
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.